304 related articles for article (PubMed ID: 25739703)
1. Optimizing quality of life in multiple myeloma patients: current options, challenges and recommendations.
Maes H; Delforge M
Expert Rev Hematol; 2015 Jun; 8(3):355-66. PubMed ID: 25739703
[TBL] [Abstract][Full Text] [Related]
2. Elderly patients with multiple myeloma: towards a frailty approach?
Zweegman S; Engelhardt M; Larocca A;
Curr Opin Oncol; 2017 Sep; 29(5):315-321. PubMed ID: 28763310
[TBL] [Abstract][Full Text] [Related]
3. Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients?
Palumbo A; Mateos MV; Bringhen S; San Miguel JF
Blood Rev; 2011 Jul; 25(4):181-91. PubMed ID: 21497966
[TBL] [Abstract][Full Text] [Related]
4. Optimal management of elderly patients with myeloma.
Cerrato C; Mina R; Palumbo A
Expert Rev Anticancer Ther; 2014 Feb; 14(2):217-28. PubMed ID: 24308685
[TBL] [Abstract][Full Text] [Related]
5. Management of multiple myeloma in older adults: Gaining ground with geriatric assessment.
Wildes TM; Campagnaro E
J Geriatr Oncol; 2017 Jan; 8(1):1-7. PubMed ID: 27118356
[TBL] [Abstract][Full Text] [Related]
6. Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.
Richardson P; Jagannath S; Colson K
Clin Adv Hematol Oncol; 2006 May; 4(5):1; discussion 8; suppl 13. PubMed ID: 16830422
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
[TBL] [Abstract][Full Text] [Related]
8. Determining treatment intensity in elderly patients with multiple myeloma.
Salvini M; D'Agostino M; Bonello F; Boccadoro M; Bringhen S
Expert Rev Anticancer Ther; 2018 Sep; 18(9):917-930. PubMed ID: 29972740
[TBL] [Abstract][Full Text] [Related]
9. Management of older and frail patients with multiple myeloma in the Portuguese routine clinical practice: Deliberations and recommendations from an expert panel of hematologists.
João C; Geraldes C; Neves M; Mariz M; Trigo F
J Geriatr Oncol; 2020 Nov; 11(8):1210-1216. PubMed ID: 32601004
[TBL] [Abstract][Full Text] [Related]
10. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues.
Delforge M; Bladé J; Dimopoulos MA; Facon T; Kropff M; Ludwig H; Palumbo A; Van Damme P; San-Miguel JF; Sonneveld P
Lancet Oncol; 2010 Nov; 11(11):1086-95. PubMed ID: 20932799
[TBL] [Abstract][Full Text] [Related]
11. Multiple myeloma maintenance therapy: a review of the pharmacologic treatment.
Shank BR; Brown VT; Schwartz RN
J Oncol Pharm Pract; 2015 Feb; 21(1):36-51. PubMed ID: 24395544
[TBL] [Abstract][Full Text] [Related]
12. Management of older patients with multiple myeloma.
Gay F; Palumbo A
Blood Rev; 2011 Mar; 25(2):65-73. PubMed ID: 21295387
[TBL] [Abstract][Full Text] [Related]
13. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.
Palumbo A; Bringhen S; Mateos MV; Larocca A; Facon T; Kumar SK; Offidani M; McCarthy P; Evangelista A; Lonial S; Zweegman S; Musto P; Terpos E; Belch A; Hajek R; Ludwig H; Stewart AK; Moreau P; Anderson K; Einsele H; Durie BG; Dimopoulos MA; Landgren O; San Miguel JF; Richardson P; Sonneveld P; Rajkumar SV
Blood; 2015 Mar; 125(13):2068-74. PubMed ID: 25628469
[TBL] [Abstract][Full Text] [Related]
14. Initial treatment of nontransplant patients with multiple myeloma.
Cerrato C; Palumbo A
Semin Oncol; 2013 Oct; 40(5):577-84. PubMed ID: 24135402
[TBL] [Abstract][Full Text] [Related]
15. Management of multiple myeloma with bortezomib: experts review the data and debate the issues.
Dicato M; Boccadoro M; Cavenagh J; Harousseau JL; Ludwig H; San Miguel J; Sonneveld P
Oncology; 2006; 70(6):474-82. PubMed ID: 17283449
[TBL] [Abstract][Full Text] [Related]
16. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
[TBL] [Abstract][Full Text] [Related]
17. Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal.
Kleber M; Ihorst G; Udi J; Koch B; Wäsch R; Engelhardt M
Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):38-48. PubMed ID: 22054851
[TBL] [Abstract][Full Text] [Related]
18. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
[TBL] [Abstract][Full Text] [Related]
19. Emerging drugs in multiple myeloma.
Ghobrial IM; Leleu X; Hatjiharissi E; Hideshima T; Mitsiades C; Schlossman R; Anderson KC; Richardson P
Expert Opin Emerg Drugs; 2007 Mar; 12(1):155-63. PubMed ID: 17355220
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
Möller J; Nicklasson L; Murthy A
J Med Econ; 2011; 14(6):690-7. PubMed ID: 21892856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
